Patents by Inventor Gilles Riveau

Gilles Riveau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 28 kDa GST proteins from schistosoma for the use thereof in the treatment of inflammatory autoimmune diseases generating a Th1 and/or Th17 response
    Patent number: 9593313
    Abstract: The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kDa glutathione S-transferase protein from a schistosome selected from Schistosoma haematobium, Schistosoma mansoni, Schistosoma bovis represented respectively by the sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 for the use thereof in the treatment of an inflammatory autoimmune disease generating a response of type Th1 and/or Th17.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: March 14, 2017
    Assignees: UNIVERSITE DU DROIT ET DE LA SANTE DE LILLE 2, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE
    Inventors: Monique Capron, Mohamed El Nady, Jean-Frederic Colombel, Gilles Riveau
  • 28 KDA GST PROTEINS FROM SCHISTOSOMA FOR THE USE THEREOF IN THE TREATMENT OF INFLAMMATORY AUTOIMMUNE DISEASES GENERATING A TH1 AND/OR TH17 RESPONSE
    Publication number: 20150118259
    Abstract: The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kDa glutathione S-transferase protein from a schistosome selected from Schistosoma haematobium, Schistosoma mansoni, Schistosoma bovis represented respectively by the sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 for the use thereof in the treatment of an inflammatory autoimmune disease generating a response of type Th1 and/or Th17.
    Type: Application
    Filed: February 6, 2013
    Publication date: April 30, 2015
    Applicants: UNIVERSITE DU DROIT ET DE LA SANTE DE LILLE 2, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE
    Inventors: Monique Capron, Mohamed El Nady, Jean-Frederic Colombel, Gilles Riveau
  • Adjuvant composition comprising FHA protein or a fragment of FHA protein in its free form
    Publication number: 20050175621
    Abstract: The invention concerns the use of the FHA protein or part of the FHA protein, in free form, as adjuvant of the immune response or as immunostimulant in a human or an animal. The invention also concerns adjuvant and immunostimulatory compositions comprising FHA protein or a fragment thereof, and the use of said compositions for making vaccines.
    Type: Application
    Filed: December 9, 2002
    Publication date: August 11, 2005
    Inventors: Andre Capron, Camille Locht, Franco Menozzi, Odile Poulain-Godefroy, Gilles Riveau
  • RECOMBINANT PROTEINS OF FILAMENTOUS HAEMAGGLUTININ OF BORDETELLA, PARTICULARLY BORDETELLA PERTUSSIS, METHOD FOR PRODUCING SAME, AND USES THEREOF FOR PRODUCING FOREIGN PROTEINS OF VACCINATING ACTIVE PRINCIPLES
    Patent number: 6841358
    Abstract: A recombinant DNA containing a sequence (1) coding for a polypeptide heterologous to a filamentous haemagglutinin of Bordetella (Fha) fused within the reading frame to a sequence (2) located upstream from the first sequence. Sequence (2) codes for at least part of the Fha precursor, which part comprises at least the N-terminal region of a truncated mature Fha protein, which contains the interaction site of Fha and heparin and the secretion domain. This Fha protein is under the control of a promoter recognized by the cell polymerases of B. pertussis and is inserted into a B. pertussis cell culture, is expressed in the culture and excreted into the cell culture medium. The invention uses both the abilities of Bordetella and particularly B.
    Type: Grant
    Filed: April 19, 1995
    Date of Patent: January 11, 2005
    Assignee: Institut Pasteur De Lille
    Inventors: Camille Locht, Genevieve Renauld, Andre Capron, Gilles Riveau, Franco Menozzi, Francoise Jacob-Dubuisson
  • Adjuvant composition comprising FHA protein or a fragment of FHA protein in its free form
    Publication number: 20040047867
    Abstract: The invention concerns the use of the FHA protein or part of the FHA protein, in free form, as adjuvant of the immune response or as immunostimulant in a human or an animal. The invention also concerns adjuvant and immunostimulatory compositions comprising FHA protein or a fragment thereof, and the use of said compositions for making vaccines.
    Type: Application
    Filed: December 9, 2002
    Publication date: March 11, 2004
    Inventors: Andre Capron, Camille Locht, Franco Menozzi, Odile Poulain-Godefroy, Gilles Riveau
  • Bordetella strain expressing the FHA hybrid, liposomes and vaccines
    Patent number: 6660261
    Abstract: The invention concerns a Bordetella strain deficient in the production of toxin and expressing a hybrid protein comprising at least part of the filamentous hemagglutin (FHA) and at least part of a protein heterologous to FHA. The gene coding for the toxin has been eliminated, or at least partially deleted or mutated so as to produce an inactive toxin. This strain can be used as vaccine. The invention also concerns liposomes containing at least part of the FHA protein and at least one protein heterologous to the FHA protein, and the use of FHA for the stimulation of immune responses.
    Type: Grant
    Filed: September 16, 1999
    Date of Patent: December 9, 2003
    Assignee: Institut Pasteur de Lille
    Inventors: Nathalie Mielcarek, Camille Locht, Gilles Riveau, Odile Poulain-Godefroy, André Capron